Shares of Eli Lilly and Company (LLY) surged on Wednesday morning after the drugmaker reported higher fourth-quarter earnings and issued strong full-year 2026 guidance, driven by demand for Mounjaro and Zepbound.
The stock is currently trading at $1,104.03, up $100.57 or 10.02%, on the NYSE. The stock opened at $1,075.12 after closing Tuesday at $1,003.46. The stock has traded between $623.78 and $1,133.95 in the past 52-week period.
Eli Lilly reported fourth-quarter net income of $6.64 billion, or $7.39 per share, up from $4.41 billion, or $4.88 per share, a year earlier. On an adjusted basis, earnings rose to $7.54 per share, topping analysts' expectations of $6.93.
Revenue surged 42.6% to $19.29 billion, fueled by strong volume growth from Mounjaro and Zepbound, with key product sales reaching $13.8 billion.
Looking ahead, Lilly forecast full year earnings of $33.50 to $35.00 per share and revenue of $80 billion to $83 billion.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.